Acroanesthesia: Sensory Loss in Extremities

Acroanesthesia represents a distinct sensory deficit marked by a profound loss of tactile, thermal, or nociceptive perception isolated to the distal extremities of the human body. As a clinical sign bridging neurology, vascular medicine, and psychiatry, this manifestation often serves as a vital diagnostic indicator of underlying peripheral nerve dysfunction, microvascular compromise, or psychogenic dissociation. Understanding the multifaceted etiologies and anatomical underpinnings of acroanesthesia is essential for clinicians striving to accurately differentiate focal neuropathologies from systemic systemic and functional neurological conditions.

Acroanesthesia

1. Concise Definition

Acroanesthesia is clinically defined as the total or partial loss of cutaneous sensation occurring specifically in the distal extremities, predominantly localized to the hands, fingers, feet, or toes. It denotes a circumscribed manifestation of anesthesia where somatosensory afferent transmission is interrupted, impaired, or functionally suppressed within the acral regions of the anatomy.

Rather than denoting an independent disease entity, acroanesthesia is classified primarily as a semiological sign or clinical manifestation arising from varied etiologies. It signifies an interruption anywhere along the neuroaxis responsible for acral somatosensory signaling—ranging from the distal nerve terminals and microvascular capillary beds supplying the skin, up through peripheral nerve trunks, to central somatic representations within the cerebral cortex.

In modern diagnostic nomenclature, the phenomenon is frequently described within the framework of distal symmetric polyneuropathies, focal entrapment neuropathies, ischemic vasospastic syndromes, or functional neurological symptom disorders. Its manifestation demands rigorous diagnostic differentiation to decipher whether the perceptual void originates from an organic neurovascular lesion or an integrative neurofunctional disturbance.

2. Etymology and Linguistic Origin

The term acroanesthesia is derived from classical Greek linguistic roots that meticulously characterize the geographical and functional nature of the presentation. The prefix acro- originates from the Greek ákron (ἄκρον), meaning “extremity,” “summit,” “tip,” or the outermost part of the limbs. The component an- represents the negative prefix (ἀν-), denoting “without,” “privation,” or “absence.” The final constituent aesthesia stems from the Greek noun aísthēsis (αἴσθησις), which signifies “sensation,” “feeling,” or “sensory perception.”

Historically, the compound entered European medical lexicons during the late nineteenth century as clinical neurology coalesced into an independent scientific discipline. Prominent neurologists in France, Germany, and the United Kingdom began synthesizing precise Greco-Latin terminology to catalog subtle distinctions between paresthesias (abnormal spontaneous sensations), hyperesthesias (increased sensations), and pure regional anesthesias. The British English variant commonly maintains the classical orthography acroanaesthesia, while standard American medical terminology favors acroanesthesia.

3. Pronunciation and Grammatical Form

Acroanesthesia is pronounced phonetically as /ˌæk.roʊ.æn.əsˈθiː.ʒə/ in General American English, or /ˌæk.rəʊ.æn.iːsˈθiː.zi.ə/ in Received Pronunciation. The word functions grammatically as an uncountable abstract noun. Clinical derivatives and variants include:

• Acroanesthetic (adjective): Characterized by, relating to, or presenting with numbness in the extremities (e.g., “the patient exhibited an acroanesthetic presentation in both upper extremities”).
• Acroanaesthesia (noun): British and Commonwealth spelling variant.
• Acrohypesthesia (noun): A related variant designating an incomplete or attenuated reduction of sensation in the acral regions, as opposed to absolute sensory loss.

4. Detailed Conceptual Explanation

The physiological integrity of cutaneous sensation relies on the flawless transmission of afferent signals from the periphery to the primary somatosensory cortex. Acroanesthesia reflects a localized failure within this pathway, localized specifically to regions possessing the highest density of sensory receptors: the palmar surfaces of the hands and the plantar surfaces of the feet. These acral regions are innervated by complex networks of specialized mechanoreceptors (Meissner corpuscles, Merkel discs, Pacinian corpuscles, and Ruffini endings), free thermoreceptive nerve endings, and nociceptive unmyelinated C-fibers and thinly myelinated A-delta fibers.

When an individual experiences organic acroanesthesia, the neurochemical or electrical transmission across these receptors or their corresponding distal axons is terminated. In the classic “glove-and-stocking” distribution, this process is length-dependent. The longest sensory axons within the human nervous system—which extend from the dorsal root ganglia situated near the lower lumbar and lower cervical spinal cord all the way to the tips of the toes and fingers—are the most metabolically demanding and vulnerable structures. Any systemic disruption in axonal transport, endoneurial blood supply, or mitochondrial function disproportionately affects these terminal extensions first, giving rise to numbness that begins at the tips of the extremities.

Acroanesthesia may likewise manifest through severe vascular mechanisms. Microvascular ischemia can arrest the action potentials of terminal cutaneous nerves due to rapid oxygen and nutrient deprivation. In prolonged localized vasospasm or structural arterial occlusion, sensory transduction ceases entirely, producing a dense, cold numbness. This vascular-induced sensory cessation typically co-occurs with distinct color changes (pallor, cyanosis) and cutaneous temperature drops, contrasting with pure neuropathic lesions where cutaneous perfusion may remain clinically unremarkable.

Conversely, acroanesthesia may also emerge despite pristine structural and electrical conductivity throughout the peripheral nervous system. In functional neurological symptom disorder (conversion disorder), sensory signals are appropriately transduced by peripheral receptors and ascend the spinothalamic and dorsal column-medial lemniscal pathways to the thalamus, yet fail to reach conscious sensory awareness. Functional neuroimaging demonstrates that in non-organic acroanesthesia, hyperactivation within the limbic circuits and prefrontal monitoring networks can inhibit the primary somatosensory cortex, creating a genuinely experienced clinical anesthesia that does not respect anatomic dermatomal or peripheral nerve distributions.

5. Historical Development

The systematic study of localized distal sensory phenomena took flight in the latter half of the nineteenth century, propelled by trailblazing work in sensory physiology and clinical localization. During the American Civil War, military surgeon Silas Weir Mitchell extensively documented the sensory consequences of peripheral nerve trauma in wounded soldiers. Mitchell’s vivid observations laid the foundational ground for differentiating neurotmesis and axonotmesis from regional sensory deficits accompanied by autonomic and vasomotor dysregulation.

In 1893, German neurologist Friedrich Schultze introduced the clinical concept of akroparästhesie (acroparesthesia) to define nocturnal tingling, numbness, and burning in the hands of middle-aged women. While Schultze focused on abnormal positive sensory manifestations, his work spurred contemporary neurologists to differentiate cases involving pure tingling from those presenting with definitive sensory loss, subsequently categorized as acroanesthesia. Concurrently, French neurologist Jean-Martin Charcot at the Salpêtrière Hospital investigated regional sensory deficits, documenting cases where patients lost all tactile sensation over the hands in a sharply demarcated “gauntlet” pattern. Charcot meticulously cataloged how these patterns frequently occurred in the absence of muscular atrophy or reflex loss, contrasting “hysterical anesthesia” with the progressive, degenerative peripheral neuropathies documented by his contemporaries.

During the mid-twentieth century, advancements in electromyography, neurography, and electron microscopy fundamentally transformed the clinical comprehension of acroanesthesia. The introduction of standardized nerve conduction studies enabled practitioners to definitively locate physiological blocks and axonal degeneration. In recent decades, the discovery and biopsy validation of small-fiber neuropathies—conditions selectively damaging the unmyelinated C-fibers that escape standard electrodiagnostic testing—clarified hundreds of historically idiopathic presentations of acroanesthesia, repositioning many cases formerly labeled as functional into the realm of verifiable organic micro-neuropathology.

6. Theoretical Foundations

The academic study of acroanesthesia is grounded in the convergence of three foundational neurobiological and psychophysiological models: the Length-Dependent Dying-Back Hypothesis, the Microvascular-Ischemic Model, and the Predictive Processing Model of Somatoperception.

The Length-Dependent Dying-Back Hypothesis, primarily formulated through the metabolic models of peripheral neuropathy, posits that the structural vitality of an axon depends entirely on the anterograde transport of proteins, lipids, and mitochondria from the neuronal perikaryon. Because the dorsal root ganglion cells innervating the feet possess axons exceeding one meter in length, any disruption in axoplasmic flow or energy metabolism leads to terminal degeneration at the most distal point. As the distal axoplasm fails, sensory signaling collapses sequentially from toes to midfoot, ankles, and later to the fingertips, establishing the physical boundaries characteristic of distal symmetrical acroanesthesia.

The Microvascular-Ischemic Model emphasizes the sensitivity of neural tissue to hypoxia. Cutaneous nerves are sustained by an intricate network of microvessels known as the vasa nervorum. This theoretical framework explains acroanesthesia in disorders characterized by intense vasospasm or microangiopathy, such as systemic sclerosis and vibration-induced white finger. In these contexts, prolonged microvascular constriction triggers acute endoneurial hypoxia, halting the adenosine triphosphate (ATP)-dependent sodium-potassium pumps that maintain the resting membrane potential of sensory neurons, resulting in temporary or prolonged acroanesthetic paralysis of sensation.

The Predictive Processing Model of Somatoperception offers an advanced framework for non-organic or functional acroanesthesia. Under this neurocognitive model, perception is not merely a passive ascending stream of sensory inputs, but an active top-down generative inferential process. The brain continually matches sensory predictions against bottom-up prediction errors. In functional acroanesthesia, altered top-down attentional priors—often influenced by autonomic arousal, trauma, or health anxiety—can attenuate the sensory gain of ascending peripheral signals. As a result, even if primary afferent inputs reach the thalamus normally, they are filtered out prior to conscious processing, producing complete subjective numbness confined to the culturally or intuitively understood boundary of the hand or foot.

7. Key Components, Types, and Dimensions

Acroanesthesia can be broken down across several structural dimensions and physiological subtypes, reflecting distinct underlying mechanisms:

• Topographical Distribution:
  • Bilateral Symmetrical (Glove-and-Stocking): Typical of metabolic, toxic, or genetic distal polyneuropathies, affecting both hands and feet uniformly based on axonal length.
  • Focal/Mononeuropathic: Confined to the sensory distribution of a single peripheral nerve (e.g., median nerve numbness in carpal tunnel syndrome, mimicking partial acroanesthesia of the first three digits).
  • Circumferential Non-Anatomical: Characterized by abrupt, ring-like demarcations at the wrists or ankles that do not match any recognized peripheral nerve or dermatomal boundary, often pathognomonic of functional sensory loss.
• Modality Specificity:
  • Dissociated Acroanesthesia: Selective loss of pain and temperature sensation with preservation of light touch and proprioception (indicative of selective small-fiber impairment or central cord lesions such as syringomyelia).
  • Global (Complete) Acroanesthesia: Pan-modal loss encompassing light touch, two-point discrimination, nociception, temperature, and vibratory/proprioceptive senses.
• Temporal Dynamics:
  • Transient/Paroxysmal Acroanesthesia: Episodic sensory loss associated with cold exposure, transient ischemic episodes, or hyperventilation-induced hypocalcemia.
  • Chronic Progressive Acroanesthesia: Insidious, permanent sensory deterioration typical of unmanaged metabolic disturbances, neurodegenerative syndromes, or cumulative toxic exposure.

8. Examples and Illustrative Cases

The following case descriptions illustrate the clinical manifestation and differential diagnosis of acroanesthesia across divergent pathophysiological settings:

Case 1: Metabolic Length-Dependent Polyneuropathy
A 62-year-old male with a 15-year history of type 2 diabetes mellitus presents with insidious, symmetrical sensory loss starting in the toes and progressively ascending over two years to the mid-calf. Within the preceding three months, he noted that the fingertips of both hands felt “wrapped in thick cotton,” rendering him unable to discern coins in his pocket or manipulate fine buttons. Neurological examination reveals dense acroanesthesia to light touch and pinprick below the ankles and in a glove-like distribution over the distal phalanges of digits I through V bilaterally. Deep tendon reflexes at the Achilles tendon are absent. The pattern exemplifies length-dependent axonal degeneration induced by chronic hyperglycemia and microangiopathic ischemia of the endoneurium.

Case 2: Vasospastic Cryopathic Acroanesthesia
A 29-year-old female presents with acute episodes of numbness and blanching of her fingers upon exposure to refrigerated environments. During an attack, the distal two phalanges of digits II through V turn chalky white, during which she experiences complete acroanesthesia—failing to perceive pinpricks or heat applied to the blanched zones. Upon warming, the digits transition from white to cyanotic blue and eventually hyperemic red, accompanied by severe, throbbing pain (acrodynia) as sensation returns. This transient acroanesthesia is secondary to severe, paroxysmal arteriolar vasospasm characteristic of severe primary Raynaud syndrome.

Case 3: Functional Sensory Deficit (Conversion Presentation)
A 34-year-old graphic designer presents to the clinic reporting an abrupt, total loss of sensation over her right hand following an acute workplace stressor. Physical examination identifies an absolute loss of all sensory modalities—tactile, thermal, vibratory, and pinprick—terminating sharply in a precise horizontal line around the circumference of the right wrist. Vibration testing using a 128 Hz tuning fork over the right radial styloid is reported as absent, but felt normally over the adjacent ulnar styloid of the exact same bone (an anatomical impossibility in organic nerve injury, as bone conduction transmits vibration uniformly across the radial-ulnar bridge). Reflexes, motor strength, and nerve conduction studies are entirely normal, confirming non-organic, functional acroanesthesia.

9. Measurement and Clinical Assessment

The diagnostic evaluation of acroanesthesia necessitates a multi-tiered approach integrating bedside somatosensory mapping, electrophysiological investigation, autonomic testing, and histopathology.

Initial bedside evaluation relies on mapping the physical boundaries of the sensory loss to discern whether the deficit conforms to a peripheral nerve, a spinal dermatome, or a length-dependent pattern. Semmes-Weinstein monofilaments are routinely utilized to objectively quantify cutaneous pressure thresholds, with the 5.07 (10-gram) monofilament serving as the international clinical threshold for identifying loss of protective sensation in acral regions. Tactile spatial resolution is evaluated using static and dynamic two-point discrimination discs, where normal acral pulp thresholds typically range between 2 to 6 millimeters.

Quantitative Sensory Testing (QST) provides a psychophysical measurement of thermal and nociceptive thresholds, elucidating the functional state of A-delta and C-fibers. To evaluate large-fiber conduction, clinicians employ formal nerve conduction studies (NCS) and electromyography (EMG). Sensory Nerve Action Potentials (SNAPs) are recorded from the sural, superficial peroneal, radial, and median nerves. A marked reduction in SNAP amplitudes with relatively preserved conduction velocities signals axonal sensory neuropathy, whereas marked velocity slowing and temporal dispersion point toward demyelinating polyneuropathies.

When standard electrodiagnostic studies return normal results in the presence of demonstrable small-fiber acroanesthesia, a minimally invasive skin punch biopsy (typically 3 mm in diameter) taken from the distal leg or acral skin is considered the gold standard. Using immunohistochemistry directed against protein gene product 9.5 (PGP 9.5), pathologists quantify intraepidermal nerve fiber density (IENFD). A reduction in linear fiber density below established age- and sex-adjusted norms provides unequivocal structural evidence of small-fiber terminal loss.

10. Applications and Practical Significance

The clinical recognition and correct attribution of acroanesthesia carry immense clinical significance across several major medical disciplines:

• Preventive Diabetology and Podiatry: Acroanesthesia represents the premier risk factor for neuropathic ulceration, Charcot neuroarthropathy, and subsequent lower extremity amputation. When acral cutaneous warning signals (nociception) are silenced, repetitive microtrauma, foreign body penetration, and shear stress go unnoticed by the patient. Establishing the presence of acroanesthesia triggers early foot-care protocols, customized pressure-relieving orthotics, and patient education.
• Occupational Health and Industrial Medicine: Acroanesthesia serves as a critical diagnostic indicator for Hand-Arm Vibration Syndrome (HAVS) in industrial workers operating pneumatic drills, chainsaws, or grinders. Early detection prevents irreversible occupational sensory neuropathy and vascular thrombosis.
• Chemotherapy Management in Oncology: Many standard antineoplastic agents—including paclitaxel, oxaliplatin, and vincristine—are notoriously neurotoxic. The emergence of acroanesthesia frequently mandates immediate oncologic dose adjustments or drug substitutions to prevent permanent, debilitating peripheral nerve death.
• Neuropsychiatry and Liaison Psychiatry: The accurate differentiation of non-anatomical acroanesthesia from structural neurological disease prevents unnecessary, invasive, and costly medical interventions while redirecting patients toward appropriate cognitive behavioral therapy and physical reactivation programs.

11. Research and Empirical Evidence

Contemporary clinical trials and neuroimaging investigations have fundamentally refined our understanding of acroanesthesia and its physiological mechanisms. Seminal epidemiological studies, such as the Rochester Diabetic Neuropathy Study conducted by Dyck and colleagues, systematically demonstrated that distal sensory loss is primarily governed by axonal dying-back processes linked to cumulative glycation end-products, oxidative stress, and microvascular endoneurial hypoxia.

In the domain of small-fiber pathology, research led by Lacomis (2002) and subsequent international consortia established intraepidermal nerve fiber density as an indispensable metric, confirming that up to 40% of patients exhibiting isolated distal numbness with completely normal standard electrophysiology suffer from quantifiable structural terminal axon loss. Recent multi-center trials on chemotherapy-induced peripheral neuropathy (CIPN) have further clarified that drugs like bortezomib and taxanes cause direct neurotoxic damage to the dorsal root ganglion cells, which lack a complete blood-nerve barrier, thereby explaining the early and selective emergence of acral numbness.

Functional neuroimaging studies utilizing functional Magnetic Resonance Imaging (fMRI) have offered profound empirical insights into functional acroanesthesia. Research by Vuilleumier, Stone, and colleagues demonstrates that when tactile stimuli are presented to an acroanesthetic limb in a patient with a functional neurological disorder, the primary somatosensory cortex exhibits marked hypoactivation, while the right anterior insula, anterior cingulate cortex, and amygdala exhibit abnormal hyperactivation. This empirical evidence validates that the patient’s subjective sensory loss is neurologically instantiated at the level of central attention and perceptual awareness, firmly dispelling outdated notions of intentional malingering.

12. Cultural and Cross-Cultural Considerations

The interpretation, reporting, and psychological impact of acroanesthesia vary considerably across cultural landscapes. In Western clinical medicine, numbness is generally conceptualized as a biological sign warranting technological evaluation (e.g., neurophysiology, blood panels, MRIs). Patients in these settings typically describe the sensation using precise mechanistic language such as “pins and needles,” “deadness,” or “absence of feeling.”

In contrast, ethnopsychiatric and medical anthropological research indicates that in many non-Western populations, sensory disturbances in the extremities are frequently embedded within holistic idioms of distress. In traditional Chinese medicine (TCM) frameworks, distal numbness (bì zhèng or obstruction syndrome) is conceptualized as an impairment in the flow of vital energy (Qi) and blood stagnation caused by wind, cold, or dampness invading the meridians. Patients from these cultural traditions may present with complaints of internal heaviness, coldness, or life-force depletion rather than an isolated neuroanatomical deficit.

Moreover, cross-cultural differences in pain and sensory tolerance significantly influence when an individual seeks clinical intervention. In agrarian or manual-labor economies, mild acroanesthesia may go unaddressed until secondary complications—such as visible cutaneous burns, severe ulcerations, or functional motor impairment—manifest, because subtle sensory reductions in the fingertips or soles are often viewed as a normal adaptation to manual exertion.

13. Criticisms, Debates, and Limitations

The clinical construct of acroanesthesia remains the subject of ongoing nosological debates within clinical neurology and psychiatry. A central criticism concerns the diagnostic ambiguity of the term itself. Historically, acroanesthesia has been applied interchangeably with acroparesthesia, hypesthesia, or simply peripheral neuropathy. Many modern clinicians argue that the term has become archaic, preferring anatomically precise descriptions such as “distal length-dependent sensory loss” or “acral sensory neuropathy,” which carry explicit pathophysiological connotations and therapeutic guidance.

Another continuous debate centers on the diagnostic boundary separating late-stage functional sensory deficits from idiopathic small-fiber neuropathies. Prior to the widespread adoption of PGP 9.5 skin biopsies, many patients presenting with non-dermatomal acroanesthesia were prematurely categorized as having functional (psychogenic) symptoms. The subsequent revelation that a substantial proportion of these individuals possessed profound intraepidermal nerve fiber reductions sparked widespread critique regarding the reliability of bedside functional neurological tests, emphasizing that bizarre or non-classical sensory patterns can occasionally emerge from complex, patchy microvascular or small-fiber insults.

Finally, a critical limitation in current therapeutics is the clinical irreversibility of established neurodegenerative acroanesthesia. While symptomatic neuropathic pain can often be mitigated pharmacologically using gabapentinoids, serotonin-norepinephrine reuptake inhibitors, or tricyclics, there are currently no universally effective disease-modifying agents capable of regenerating terminal sensory axons once extensive distal dying-back has concluded. Thus, the management of organic acroanesthesia remains largely confined to secondary injury prevention, glycemic or metabolic optimization, and occupational accommodations.

14. Related Terms and Differential Distinctions

Accurate clinical diagnosis requires that acroanesthesia be clearly delineated from a range of related sensory and vascular phenomena:

• Acroparesthesia: Characterized by spontaneous, abnormal sensations in the extremities (such as tingling, prickling, or “pins and needles”) without necessarily involving a loss of sensation. Acroparesthesia is a positive sensory symptom, whereas acroanesthesia is fundamentally a negative sensory symptom (absence of feeling).
• Acrodysesthesia: Refers to unpleasant, abnormal, or painful sensations provoked by normal stimuli or occurring spontaneously in the extremities, often described as burning, searing, or electrical shocks.
• Acrocyanosis: A persistent, painless, symmetric cyanotic discoloration of the hands and feet caused by vasospasm of small cutaneous arterioles combined with compensatory dilatation of postcapillary venules. Sensation is typically preserved, unlike the dense numbness found in acroanesthesia.
• Raynaud Phenomenon: An episodic, paroxysmal vasospastic disorder characterized by sequential triphasic color changes (pallor, cyanosis, erythema) triggered by cold or emotional stress. Acroanesthesia is frequently present, but strictly limited to the duration of the ischemic (blanched) phase.
• Erythromelalgia: A rare neurovascular peripheral condition marked by episodes of burning pain, intense erythema, and increased skin temperature in the extremities; the diametric opposite of ischemic or anesthetic presentations.
• Glove-and-Stocking Hypesthesia: A broader descriptive clinical term denoting attenuated (but not necessarily completely absent) sensation across the hands and feet, typically indicative of early length-dependent polyneuropathy.

15. Summary and Key Takeaways

Acroanesthesia is a crucial semiological sign marked by the localized loss of cutaneous sensory perception in the distal regions of the limbs. Whether driven by length-dependent metabolic polyneuropathy, chemotherapy-induced toxicity, severe microvascular vasospasm, or altered predictive processing in functional neurological symptom disorder, it demands a comprehensive, multimodal clinical assessment.

Distinguishing between organic patterns—which reflect length-dependent axonal degeneration or terminal nerve damage—and functional patterns requires meticulous bedside mapping, quantitative electrophysiology, and, when indicated, histological quantification of intraepidermal nerve fibers. Early identification of acroanesthesia is vital for safeguarding patients from unperceived cutaneous trauma, preventing catastrophic diabetic ulcers, optimizing industrial ergonomic safety, and formulating individualized therapeutic strategies across neurological, rheumatologic, and psychiatric contexts.

In conclusion, recognizing acroanesthesia as both a physical marker and a subjective sensory void underscores the deep integration of the human somatosensory system. When acral nerve terminals fail to relay environmental contacts to consciousness, the resulting deficit challenges physical safety, functional independence, and overall somatic embodiment, demanding prompt diagnostic precision and compassionate clinical management.

References

• Dyck, P. J., & Thomas, P. K. (2005). Peripheral Neuropathy (4th ed.). Elsevier Saunders. https://www.elsevier.com/books/peripheral-neuropathy/dyck/978-0-7216-9491-7
• England, J. D., Gronseth, G. S., Franklin, G., Miller, R. G., Asbury, A. K., Carter, G. T., Cohen, J. A., Fisher, M. A., Howard, J. F., Kinsella, L. J., Latov, N., Lewis, R. A., Low, P. A., & Sumner, A. J. (2005). Distal symmetric polyneuropathy: A definition for clinical and epidemiological research. Neurology, 64(2), 199–207. https://doi.org/10.1212/01.WNL.0000149522.32823.EA
• Lacomis, D. (2002). Small-fiber neuropathy. Muscle & Nerve, 26(2), 173–188. https://doi.org/10.1002/mus.10181
• Mitchell, S. W. (1872). Injuries of Nerves and Their Consequences. J. B. Lippincott & Co. https://archive.org/details/injuriesofnerves00mitc
• Stone, J., Carson, A., & Hallett, M. (2016). Functional neurological disorders. Handbook of Clinical Neurology, 139, 1–655. https://doi.org/10.1016/B978-0-12-801772-2.00001-X